Literature DB >> 17508475

Tuberculosis in HIV-infected patients in Croatia between 1986 and 2005.

Ivan Puljiz1, Josip Begovac.   

Abstract

A retrospective medical chart review was performed on 65 HIV-infected patients with tuberculosis hospitalized between 1986 and 2006 at the University Hospital for Infectious Diseases "Dr. Fran Mihaljević", Zagreb. Thirty two patients presented with pulmonary involvement, 13 with extrapulmonary, and 20 patients had disseminated tuberculosis. Forty five patients had an abnormal chest X-ray. Mycobacterium tuberculosis was identified in 35 (53.9%) patients. Ten (15.3%) of 65 patients had already been receiving antiviral therapy, while another 31 (47.7%) initiated antiviral therapy after antituberculosis therapy. Tuberculosis-associated immune reconstitution inflammatory syndrome was observed in 11/27 (40.7%) patients. Forty one patient received the standard six month course of antituberculous therapy, while in 12 patients the therapy was prolonged. Twenty one patient (32%) experienced an adverse event to antituberculosis drugs. Twelve patients died (18.5%). After the introduction of highly active antiviral therapy (HAART) the mortality decreased. The incidence of tuberculosis in HIV-infected patients in Croatia is increasing, and tuberculosis is still an important opportunistic infection in our HIV-infected patients.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17508475

Source DB:  PubMed          Journal:  Coll Antropol        ISSN: 0350-6134


  2 in total

1.  Tuberculosis-Associated Immune Reconstruction Inflammatory Syndrome (TB-IRIS) in HIV-Infected Patients: Report of Two Cases and the Literature Overview.

Authors:  Klaudija Viskovic; Josip Begovac
Journal:  Case Rep Infect Dis       Date:  2013-04-18

2.  Prevalence and risk factors of paradoxical tuberculosis associated immune reconstitution inflammatory syndrome among HIV-infected patients in Beijing, China.

Authors:  Ming Xue; Ruming Xie; Yu Pang; Shuo Yan; Yanni Du; Chunshuang Guan; Budong Chen
Journal:  BMC Infect Dis       Date:  2020-07-31       Impact factor: 3.090

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.